OKYO PHARMA LTD (OKYO) Stock News
NASDAQ:OKYO - Nasdaq - GG00BMFG5F62 - Common Stock - Currency: USD
OKYO Latest News, Press Relases and Analysis
OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod
Urcosimod in Phase 2 clinical trial for Neuropathic Corneal Pain shown to have Long-Term StabilityUrcosimod stable in single-use ampoules for more than 2½...
OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod
OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain
LONDON and NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing...
OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain
OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod
OKYO Pharma Announces Chairman and CEO Acquire Shares
LONDON and NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing...
OKYO Pharma Announces Chairman and CEO Acquire Shares
Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited
OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter
LONDON and NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing...
OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter
OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding
LONDON and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing...
OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding
OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference
OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference
LONDON and NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing...
OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain
OK-101 is the first drug candidate to enroll patients specifically diagnosed with Neuropathic Corneal Pain (NCP) in a clinical trialThe Phase 2 trial is...
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain
OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain
Neuropathic corneal pain (NCP) is listed in the National Organization for Rare Disorders (NORD) as an orphan diseaseOKYO is the first company to have an...
OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain
OKYO Pharma Announces Chairman Acquires Shares
OKYO Pharma Announces Chairman Acquires Shares
OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease
LONDON and NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing...
OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease
OKYO Pharma CEO Interview to Air on Bloomberg TV
LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing...
OKYO Pharma CEO Interview to Air on Bloomberg TV
OKYO Pharma Announces Chairman Acquires Shares
LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing...
OKYO Pharma Announces Chairman Acquires Shares
OKYO Pharma Announces Chairman Acquires Shares
LONDON and NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing...
OKYO Pharma Announces Chairman Acquires Shares
OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
LONDON and NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing...
OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use
LONDON and NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing...
OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024OK-101 is believed to be the first IND...